- Citations, last 5 years
- 3 025
- Works, last 5 years
- 28
- h-index
- 48
- Scientists listed
- 0
- Grants since 2016
- 8
Grants received
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease
Eric Siemers · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development
Eric Siemers · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease
William Goure · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease
Eric Siemers · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease
Eric Siemers · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild
Jeffrey L Ives · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U01
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild
Jeffrey L Ives · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2018 · research · R41
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.
William L Klein · Acumen Pharmaceuticals (United States) · funded by National Institutes of Health